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Abstract 
Regulatory T cells (Tregs) are central to the maintenance of self-tolerance and tissue homeostasis. 
Markers commonly used to define human Tregs in the research setting include high expression of 
CD25, FOXP3 positivity and low expression/negativity for CD127. Many other markers have been 
proposed, but none unequivocally identifies bona fide Tregs. Tregs are equipped with an array of 
mechanisms of suppression, including the modulation of antigen presenting cell maturation and 
function, the killing of target cells, the disruption of metabolic pathways and the production of anti-
inflammatory cytokines. Treg impairment has been reported in a number of human autoimmune 
conditions and includes Treg numerical and functional defects and conversion into effector cells in 
response to inflammation. In addition to intrinsic Treg impairment, resistance of effector T cells to 
Treg control has been described. Discrepancies in the literature are common, reflecting differences in 
the choice of study participants and the technical challenges associated with investigating this cell 
population. Studies differ in terms of the methodology used to define and isolate putative regulatory 
cells and to assess their suppressive function. In this review we outline studies describing Treg 
frequency and suppressive function in systemic and organ specific autoimmune diseases, with a 
specific focus on the challenges faced when investigating Tregs in these conditions.  
Keywords: regulatory T cells, self-tolerance, autoimmune disease, autoimmune liver disease 
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1. Introduction 
Regulatory T cells (Tregs) are a heterogeneous population of lymphocytes central to the regulation of 
self tolerance and the maintenance of tissue homeostasis [1]. Although ‘suppressor T cells’, as they 
were originally named, had first been described in 1970 [2], our understanding of this population 
became clearer in the 1990’s when Hall et al. (1990) showed that the CD4pos T cells expressing the α-
chain of the IL2 receptor, CD25, were able to promote CD4 and CD8 T cell-mediated allograft 
unresponsiveness in cyclosporine-A treated mice [3]. Subsequently, seminal studies performed by 
Sakaguchi and colleagues demonstrated that the 10% of CD4pos T cells expressing CD25 were 
essential for the maintenance of self tolerance in mice [4-6]. Several groups then reported that, in 
humans, CD4posCD25pos/high cells were phenotypically similar to their murine counterparts, and that 
this population was able to suppress the proliferation of CD4posCD25neg cells in vitro [7-10]. In 2003, 
the transcription factor forkhead box P3 (Foxp3), was shown to control the generation and function of 
murine Tregs [11-13] and later, in humans, FOXP3 was shown to be expressed predominantly by the 
CD4pos cells expressing the highest level of CD25 [14].  
Since then, elevated Treg frequencies have been reported in patients with various forms of neoplasia, 
such as breast cancer [15-19], melanoma [20-22] and leukaemia [23-25], where they are believed to 
dampen anti-tumour immune responses and promote malignancy. Similarly, Tregs can limit anti-
pathogen immunity: high Treg frequency and function are associated with the persistence of infection 
with hepatitis C virus [26, 27], mycobacterium tuberculosis [28-30] and the malarial parasite [31-33]. 
Conversely, Treg defects have been shown to contribute to the loss of tolerance in human 
autoimmune diseases . In this review, current evidence supporting a role for Treg impairments in 
systemic [systemic lupus erythematosus (SLE)] and organ specific [multiple sclerosis (MS), type-1 
diabetes (T1D), rheumatoid arthritis (RA), autoimmune thyroid disease, psoriasis, inflammatory 
bowel disease (IBD) and autoimmune liver disease] autoimmune disorders will be discussed, with a 
particular focus on the challenges that might be encountered when investigating human Tregs in these 
conditions. 
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2. Definition of regulatory T cells 
The term ‘regulatory T cell’ or ‘Treg’ encompasses a range of cell populations specialised to exert 
cell extrinsic immunosuppression. Tregs regulate the natural course of protective immune responses 
in order to limit collateral tissue damage and autoimmunity. Several human Treg subsets have been 
described, including CD8pos Tregs [34], IL10- producing Tr1 cells [35] and Th3 cells, which primarily 
suppress via the secretion of TGFβ [36]. In addition to Tregs, a newly described population of 
regulatory B cells also contributes to immunosuppression both directly and via enhancement of Treg 
function [37]. The most extensively studied human Treg subset is characterised by high constitutive 
expression of the IL2 receptor α-chain, CD25 [7-9]. In humans, the CD25high population is enriched 
for the transcription factor FOXP3 [14], which is responsible for the transcriptional regulation of 
genes involved in the Treg phenotypic and functional signature, such as cytotoxic T lymphocyte 
antigen-4 (CTLA-4) [38]. Identifying and isolating human Tregs in the laboratory can be challenging; 
in contrast to the murine model, the expression of CD25 [5, 39] and FOXP3 [40, 41] increases 
transiently upon activation also on effector CD4 T cells. Moreover, FOXP3 being an intracellular 
protein, it cannot be readily used for the isolation of Tregs for functional studies. In humans, within 
the CD4posCD25high population, differential expression of the α-chain of the IL7 receptor, CD127, 
enables distinction between bona fide Tregs, which are typically CD127neg/low, and activated effector T 
cells, which are CD127pos. In the CD4posCD25high population, CD127 expression is inversely 
correlated with suppressive function [42-44]. 
3. Mechanisms of suppression 
There are four basic mechanisms that Tregs use to suppress immune responses (Figure 1, A); the 
modulation of antigen presenting cell (APC) maturation and function, the killing of target cells, the 
disruption of metabolic pathways and the production of anti-inflammatory cytokines [45].  
3.1. Modulation of antigen presenting cell maturation and function 
CD80 and CD86, expressed by APCs, provide essential co-stimulatory signals by binding CD28 on T 
cells during antigen presentation. CD80 and CD86 also bind CTLA-4, expressed by a subset of Tregs. 
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Direct interactions between APCs and Tregs have been recorded by intravital microscopy in vivo [46, 
47]. The interaction between CTLA-4 and CD80, leads to CD80 mRNA down-regulation [48] and a 
reduction in the APC cell surface expression of CD80 and CD86 [48, 49]. In mice and humans, 
CTLA-4 can also lead to physical removal of CD80 and CD86 from the APC cell surface by trans-
endocytosis and degradation [50]. By lowering the expression of the co-stimulatory molecules CD80 
and CD86, Tregs limit the ability of APCs to initiate an adaptive immune response. 
3.2. Killing of target cells 
There is evidence that Tregs from mice and humans express molecules capable of triggering effector 
T cell apoptosis, such as Granzymes A and B [51-55] and perforin [51, 54]. Granzymes, released from 
cytolytic granules, enter target cells via perforin pores, leading to the activation of the caspase 
pathway and to apoptotic cell death. Tregs also express Galectin-9 [56, 57] which, in mice, triggers 
apoptosis upon binding the T cell immunoglobulin and mucin domain-3 (TIM-3) expressed by 
activated effector T cells [58]. Recent studies have, however, failed to document a direct interaction 
between the human Galectin-9 and TIM-3 molecules [59], suggesting that Galectin-9 could act 
independently of TIM-3 in this setting. 
3.3. Disruption of metabolic pathways 
A key mechanism of metabolic disruption is mediated by CD39. CD39 is an ectonucleotidase 
expressed constitutively by murine Tregs [60, 61], which catalyses the degradation of adenosine 
triphosphate (ATP) – which is a predominantly pro-inflammatory molecule – into adenosine 
diphosphate (ADP) and adenosine monophosphate (AMP). The importance of CD39 expression has 
been demonstrated using Tregs from CD39 knock-out mice, which have a 50 to 60% reduction in 
their ability to suppress T cell proliferation compared to those from wild-type mice [60].  CD39 is 
also expressed by a subset of human Tregs [61, 62]. ADP/AMP, generated by ATP hydrolysis, is 
subsequently degraded into adenosine by a second enzyme, CD73, which is also expressed 
constitutively by murine Tregs and by a small proportion of human Tregs [63]. The hydrolysis 
cascade initiated by CD39 culminates in the production of adenosine, which has multiple anti-
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inflammatory properties, including the dampening of effector T cell activation and proliferation [64, 
65] and the generation of Tregs [66]. Studies have suggested that CD39pos Tregs are specialised in 
suppressing IL17 production [62]. 
3.4. Production of anti-inflammatory cytokines 
Tregs also secrete the anti-inflammatory cytokines, TGFβ [67-69], IL10 [70, 71] and IL35 [72]. 
Evidence from murine studies suggests that suppression mediated by cytokines is of particular 
importance at environmental interfaces, such as the gut, skin and lungs [73-75]. Cell surface TGFβ, 
also known as latency associated peptide (LAP), is also expressed by Tregs [76]. 
3.5. Additional markers of Tregs 
Novel strategies for Treg identification, frequently based on the removal of contaminating activated 
effector T cells, have been documented. The expression of the IL1 receptor type I/II 
(CD121a/CD121b) has, for example, been used to distinguish FOXP3pos Tregs from activated 
FOXP3pos or FOXP3neg effector T cells [77]. Similarly, CD49d has been used to identify 
contaminating activated effector T cells [78]. Since terminally differentiated effector T cells are 
negative for CD27, a TNF receptor family member, Tregs have also been defined by the co-
expression of CD27 and CD25 [79].  
The Treg population has also been subdivided according to the expression of inducible co-stimulator 
(ICOS) [80, 81]. FOXP3posICOSneg cells produce TGFβ whereas the FOXP3posICOSpos subset secretes 
both IL10 and TGFβ [82]. Miyara et al. [83] subdivided Tregs according to the expression of FOXP3 
and CD45RA, a marker of naive T cells. FOXP3highCD45RAneg cells are activated/memory Tregs, 
positive for Ki-67 – a nuclear protein expressed by proliferating cells – whereas 
FOXP3mediumCD45RAneg cells, although suppressive in vitro, have the potential to revert to a pro-
inflammatory state. The FOXP3posCD45RApos population are Ki-67neg resting Tregs that acquire 
memory Treg phenotype and function after TCR stimulation in vitro and in vivo [83].The expression 
of CD45RO, which defines memory T cells, has also been used to distinguish activated/memory and 
naive Treg populations [84]. 
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The central role of Tregs in the protection from autoimmunity is exemplified by the observation that 
Scurfy mice, with loss-of-function mutations in the Foxp3 gene, are afflicted with a fatal, multi-organ 
lymphoproliferative disease with multiple autoimmune manifestations [11, 85]. Interestingly, in the 
human equivalent of the disease – the immunodysregulation, polyendocrinopathy, enteropathy X-
linked (IPEX) syndrome [6] – different FOXP3 mutations lead to differences in the nature/degree of 
Treg impairment and, therefore, result in diverse clinical phenotypes. Thus, although in some IPEX 
cases CD4posCD25high cells expressing FOXP3 protein are present at normal frequencies, their 
capacity to suppress is impaired [86]. This observation demonstrates the potential for inherent 
diversity in terms of clinical phenotypes and, consequently, laboratory findings, highlighting the 
requirement for careful patient selection and interpretation of experimental findings in this field. 
Defective Treg numbers and/or function have been reported in several autoimmune diseases [87-89]. 
However, because of the technical challenges associated with studying human Tregs, reports are at 
times inconsistent or even contradictory. 
4. Technical challenges 
There are several technical challenges in the study of human Tregs. Firstly, no combination of the 
surface markers described herein enables researchers to identify a homogenous Treg population. In 
fact, the majority of the defining markers – CD25 [39], FOXP3 [90, 91] and CTLA-4 [92] for 
example – are also increased during effector T cell activation. For this reason, investigators often 
choose a combination of different Treg markers in their experimental setting, relying on standard 
protocols, as well as on personal experience.  
The most common way to assess Treg function is based on the ability of these cells to suppress target 
cell proliferation. The ‘proliferation assay’, pioneered by Thornton and Shevach in 1998 [41], relies 
on the isolation of the putative regulatory and responder cell populations either immunomagnetically 
or by fluorescence activated cell sorting (FACS). Responder cells are then activated, commonly under 
polyclonal stimulation, in the absence or presence of the regulatory population. After a defined period 
of time, proliferation is examined. Proliferation can be measured using carboxyfluorescein 
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succinimidyl ester (CFSE) or 3H-thymidine-based assays. CFSE-based assays have a number of 
advantages over 3H-thymidine-based assays. CFSE can be used to label the responder cell population 
exclusively, whereas 3H-thymidine measures the proliferation of both regulatory and responder cell 
populations [93-95]. Moreover, in contrast to CFSE, 3H-thymidine-based assays only assess 
proliferation during the short time-span in which 3H-thymidine is present in the co-culture [93]. 
CFSE-based assays also allow for cytofluorometry to be performed concurrently, to examine 
proliferation of more well-defined cell populations. However, CFSE staining requires the use of a cell 
number larger than 3H-thymidine-tested proliferation, and therefore this approach is not always 
feasible when only small numbers of cells are available [96]. 	
The isolation method utilised is also an important factor to consider. Compared to immunomagnetic 
isolation, FACS-based protocols give higher purity and also allow for the concomitant use and 
analysis of several Treg markers, therefore enabling better definition of the Treg population. 
However, FACS typically gives lower yields than immunomagnetic isolation, and so this method is 
not applicable to small samples.  
One of the most profound challenges associated with Treg research is to assess frequency, phenotype 
or function at the site of inflammation. In the case of RA or MS, for example, this can be overcome to 
some extent as the inflamed region is accessible. However, even in these cases, it can be difficult to 
ascertain whether Treg defects are caused by systemic factors or factors localised to the site of 
inflammation [96], especially in the absence of properly matched control samples obtained from 
healthy individuals. Assays are always limited by their ability to reproduce the characteristics of the 
inflammatory site in vitro. Despite this, studies investigating Tregs in autoimmune disease have 
provided a wealth of information, which collectively point to Treg defects as a key contributor to 
immune tolerance breakdown in autoimmunity (Figure 1, B). 
5. Regulatory T cells in autoimmune disease 
In the following sections, studies investigating the frequency and suppressive function of Tregs in the 
archetypal non-organ specific autoimmune disease SLE, and the organ specific autoimmune diseases 
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MS, T1D, RA, autoimmune thyroid disease, psoriasis and IBD will be discussed. Information about 
the findings of individual studies, and details about the markers used to define Treg populations, can 
be found in Table 1. 
5.1. Circulating regulatory T cell frequencies 
In SLE [97-109], MS [61, 62, 110-118] and RA [97, 119-125] there are reports documenting 
decreased, normal and increased circulating Treg frequencies relative to health. Reports are also 
discordant in autoimmune thyroid disease [126-130] and psoriasis [131-134], in which decreased and 
normal Treg frequencies have been observed. Similarly, although the majority of reports show 
numerical Treg defects in IBD [135-138], one study found increased frequencies [139]. While most 
studies have agreed that T1D patients have a normal frequency of circulating Tregs [43, 140-144], 
reduced frequencies were found in one recent study [145] (Table 1). In support of a defect of  Tregs in 
the development of autoimmunity, CD4posCD25posFOXP3pos Tregs are also reduced in frequency in 
patients with undifferentiated connective tissue disease, which is regarded as an early-stage 
connective tissue/systemic autoimmune disease [146]. The reasons behind the reported 
inconsistencies are not fully understood, but there are a number of non-mutually exclusive 
explanations, outlined henceforth. 
One potential explanation for the observed discrepancies is a lack of standardisation between studies 
due to the absence of a uniformly recognised marker able to reliably define a homogenous human 
Treg population. The inevitable result is the use of distinct combinations of Treg markers, which 
define the real Treg population with varying degrees of accuracy. This phenomenon is apparent in the 
studies considered in this review (Table 1). In MS, for example, studies defining Tregs as 
CD4posCD25pos/high [110-113, 117, 118], CD4posCD25posFOXP3pos [114] or CD4posCD45ROnegCD25high 
[115] cells have reported increased or equivalent Treg levels relative to health, whereas those using 
CD39 positivity [61, 62] and/or CD127 negativity [62, 116] as alternative/additional markers have 
documented decreased Treg frequencies. Similarly, in psoriasis, normal frequencies of 
CD4posCD25high [133, 134] or CD4posCD25posFOXP3pos [132] cells have been reported in some studies 
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while reduced frequencies have been described when high CD25 expression is considered in 
combination with FOXP3 positivity [131]. In one study examining the frequency of CD4posCD25pos 
cells in RA, the frequency was increased [119], whereas studies using more sophisticated gating 
strategies, encompassing high CD25 expression, FOXP3 positivity or CD127 negativity, report 
normal [97, 120-122] or decreased [123-125] Treg frequencies. 
There are two notable ways in which alternative gating strategies could influence study outcome. 
Firstly, sophisticated gating protocols may more thoroughly eliminate contaminating activated 
effector T cells, allowing subtle Treg defects to be ‘revealed’. Secondly, by focusing on Treg 
subpopulations, alternative gating strategies may uncover numerical defects unique to specific 
patterns of autoimmunity. These two explanations could underlie the aforementioned findings in MS; 
the removal of CD127pos cells eliminating contaminating activated effector T cells, and the use of 
CD39 as a Treg marker uncovering defects within this specialised Treg subpopulation. 
It is clear, however, that the use of different Treg markers cannot fully explain the discrepancies 
observed in these autoimmune conditions. In SLE, for example, the same Treg markers 
(CD4posCD25pos/highFOXP3pos) have, in different studies, yielded results consistent with increased 
[104, 107] and decreased [102, 109, 147] Treg frequencies. Similar inconsistencies are apparent when 
considering CD4posCD25pos/high cells in RA [97, 119-123, 125] and autoimmune thyroid disease [127-
129]. 
In light of this, it should be noted that flow cytometry gating is, to some extent, subjective. Even with 
gold standard staining techniques, appropriate experimental controls and sophisticated analysis 
software, the placing of gates still depends partly on researcher selection. Studies using the same 
defining Treg markers are, therefore, not necessarily comparable. An excellent example of this is the 
placing of CD25 gates; there is currently no consensus about what constitutes ‘high’ or ‘bright’. The 
interpretation of Treg research is further complicated in the absence of clear and detailed information 
about gating methodology. 
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It is also important to point out that regulatory T cell frequencies in autoimmune disease are 
influenced by disease stage and treatment regimen. In SLE, for example, Tregs have been reported to 
be less numerous in patients with active [99, 101, 105] or newly diagnosed [100] disease compared to 
those with inactive disease. In MS, disease duration is correlated with the frequency of memory 
Tregs, defined by the expression of CD45RA. Patients with short disease duration have a lower 
frequency of both naïve and memory Treg subsets, while the frequency of memory Tregs in age-
matched subjects with chronic disease is equivalent to that seen in health [116]. In the context of RA, 
while a normal frequency of Tregs was found in patients with well managed disease, a lower 
frequency was found in patients with early/active disease [125]. Additionally, although Ehrenstein et 
al. (2004) did not find numerical Treg defects in RA, the frequency of Tregs increased significantly 
over time in patients responding to anti-TNFα therapy [120]. Treg frequency is also influenced by 
disease stage and treatment regimen in psoriasis. Tregs are found at lower frequencies in untreated 
patients compared to health. Moreover, in patients responding to anti-TNFα therapy, Treg frequencies 
increase significantly during treatment, while in non-responders Treg frequency remains stable or 
decreases during therapy [131]. Additionally, photo(chemo)therapy treatment for psoriasis increases 
Treg frequency in patients who originally had a numerical Treg impairment [132]. Similarly, in IBD, 
Treg frequencies are lower in patients with active disease compared to those with inactive disease 
[137]. Treatment with the anti-TNFα monoclonal antibody Infliximab treatment increases Treg 
frequency in IBD, particularly in patients responding to therapy [138, 148]. These observations 
demonstrate that Treg frequencies in autoimmune diseases are heavily influenced by disease stage and 
treatment regimen, highlighting the need to carefully consider these variables when interpreting 
published reports.  
5.2. Circulating regulatory T cell function  
In SLE [100-104, 106, 107, 109, 147, 149], T1D [140-144, 150], RA [119-123, 125] and autoimmune 
thyroid disease [127-130], studies have reported either normal or decreased Treg suppressive abilities 
compared to health. Studies are in agreement that Tregs are impaired in MS [62, 110-112, 114-118, 
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151] and psoriasis [131-134], whereas in IBD Tregs have suppressive abilities comparable to healthy 
subjects (HS) [137, 152].  
Conflicting reports about Treg function in autoimmune disease can be accounted for using the 
explanations discussed in relation to Treg frequency. The lack of a universal human Treg marker has 
led to the use of diverse Treg gating strategies for the purposes of Treg isolation by FACS (Table 1). 
In RA, for example, although no defects were noted when CD4posCD25pos/high cells were used as Tregs 
[119-121, 123, 125], a reduced ability to suppress proliferation was apparent when CD127 negativity 
was used as an additional Treg marker [122]. The use of different Treg markers cannot adequately 
account for all of the discrepancies noted when considering Treg function; in SLE [100, 101, 103, 
106, 149], T1D [140, 141, 143, 144, 150] and RA [119-121, 123, 125], the same markers 
(CD4posCD25pos/high) have, in some instances, yielded results consistent with Treg functional 
impairment, while in others a preserved function was reported.  
Experimental findings can also be influenced by patient selection. This is particularly apparent in MS, 
which has four distinct pathological patterns that differ in terms of clinical course: acute, relapsing 
remitting (RR), primary progressive (PP) and secondary progressive (SP) disease. For example, Tregs 
from acute [115] or RR-MS [114] patients, but not SP-MS patients [112], are less able to suppress 
responder cell proliferation compared to those from HS, and defects are more pronounced during 
episodes of relapse compared to periods of remission [114]. Additionally, Venken et al. (2008) 
isolated CD4posCD25highCD127lowCD45RApos naïve and CD4posCD25highCD127lowCD45RAneg memory 
Treg subsets, and found that in RR-MS, naïve and memory Tregs were impaired in their ability to 
suppress proliferation, while in the chronic disease state, the suppressive ability of memory Tregs was 
equivalent to that found in health [116]. This study highlights the importance of patient selection but 
also demonstrates that functional defects can be specific to particular Treg sub-populations. 
Most studies have analysed Treg suppression by assessing the ability of Tregs to limit effector CD4 T 
cell proliferation. It is, however, becoming increasingly clear that Tregs can suppress a range of 
effector cell functions mediated by several cell populations. In MS, studies have shown that 
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CD4posCD25pos/high Tregs are impaired in their ability to suppress IFNγ production [110, 111] while 
CD4posCD25posCD127negCD39pos Tregs have a reduced ability to suppress IL17 production [62]. 
Similarly, in RA, although CD4posCD25high Tregs are able to suppress effector T cell proliferation, 
they are impaired in their ability to suppress IFNγ and TNFα production by effector T cells and 
monocytes. Interestingly, treatment with the anti-TNFα agent Infliximab enhances the ability of Tregs 
to suppress the production of these pro-inflammatory cytokines [120]. The inability of Tregs to 
suppress pro-inflammatory cytokine production has been associated with low CTLA-4 expression, 
and an inability of Tregs from RA patients to recruit CTLA-4 to the immunological synapse [153]. In 
this study, blockade of CTLA-4 in Tregs from HS abrogated suppression of T cell-derived IFNγ, 
leaving unchanged the ability to suppress proliferation [153]. These studies again demonstrate that 
functional defects can be limited to specific Treg subpopulations, while highlighting the importance 
of considering multiple readouts of suppression assays. 
Studies have also suggested that an inability to detect Treg functional defects [142] might be related 
to inappropriately low levels of effector T cell activation in vitro.  Lawson et al. (2008) found that 
lowering the concentration of anti-CD3/CD28 beads, a polyclonal T cell activation stimulus 
mimicking T cell receptor triggering, masked the Treg defect they observed in T1D patients when 
using higher concentrations [143]. This emphasises another potential hurdle when examining Treg 
function in autoimmune disease.  
Another important point to address is the fact that the prototypical Treg suppression assay cannot 
distinguish impaired Treg suppressive ability from resistance of effector T cells to Treg control. To 
overcome this, a number of studies have used cross-culture experiments in which Tregs isolated from 
patients are cultured with effector T cells from healthy subjects and vice versa. Tregs from MS 
patients are unable to suppress the proliferation of effector T cells from healthy subjects, whereas 
Tregs from healthy subjects effectively suppress the proliferation of T cells from MS patients, 
demonstrating that the immunoregulatory defect is Treg intrinsic [110, 111]. Similar findings have 
been reported in the context of psoriasis [133]. In other autoimmune conditions, the results from 
cross-culture experiments are inconclusive. In SLE, while one study suggested that defects were Treg 
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intrinsic [149], in another study the immunoregulatory defect was attributable to the effector T cell 
compartment [107]. While the reasons for these discrepancies remain unclear, the cross-culture 
approach involves major histocompatibility complex mismatches that can influence the results. 
5.3. Regulatory T cell frequency and function at the site of inflammation 
Tregs from the pancreatic draining lymph nodes (PLN) of T1D patients are both reduced in frequency 
and impaired in their ability to suppress the proliferation or IFNγ production of effector cells 
compared to Tregs from matched peripheral blood or from the PLN of non-diabetic brain dead multi-
organ donors [144]. This implies that defects can be localised to the target organ, highlighting an 
important limitation of studies focusing solely on the peripheral blood.  
On the other hand, studies examining Tregs in the cerebrospinal fluid (CSF) of MS patients have 
found elevated frequencies compared to matched peripheral blood, while this difference was not 
observed when Treg frequencies in the CSF and peripheral blood of patients with non-autoimmune 
neurological defects were compared [115, 151]. Similarly, studies investigating the frequency of 
Tregs in the synovial fluid of RA patients have documented increased frequencies relative to matched 
peripheral blood [119, 121, 123, 154]. 
These observations could suggest that Tregs migrate to the inflamed site in an attempt to dampen 
autoimmune damage, failing to accomplish this due to functional defects. Alternatively, they may 
reflect increased contamination of gated Treg populations with effector T cells, due to activation-
induced CD25 and FOXP3 expression. Studies examining the suppressive function of synovial fluid 
Tregs, reporting normal [119, 121] or impaired [122] Treg suppressive function, have suggested that 
both explanations may be valid. In the study reporting impaired Treg function, CD127 negativity was 
used as an additional Treg marker, therefore enabling more thorough exclusion of CD127 positive 
activated effector T cells. Interestingly, synovial fluid Tregs from HS were able to suppress the 
proliferation of effector T cells from RA patients, suggesting that the observed immunoregulatory 
defect was Treg-intrinsic. However, when Tregs from HS were pre-treated with RA synovial fluid, 
they were also functionally impaired, suggesting that factors present in the inflammatory 
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microenvironment promoted Treg dysfunction. Indeed, the addition of anti-TNFα reversed this effect. 
The presence of TNFα in the RA synovium altered FOXP3 transcriptional activity and induced Treg 
defects [122].  
Other studies have suggested that the pro-inflammatory milieu present at the site of inflammation may 
modulate Treg function. In IBD, the percentage of CD4posCD25high or CD4posFOXP3pos cells in the 
lamina propria or mesenteric lymph nodes is elevated, particularly within the inflamed tissue [135, 
137, 139, 152].  Moreover, Tregs isolated from the mucosal lymphoid tissue (143) or lamina propria 
[139, 152, 155] have normal suppressive activity. Although it is currently unclear why IBD persists 
despite the presence of a high frequency of Tregs with suppressive potential in the target organ, it 
should be noted that in vitro assays cannot always reflect all of the characteristics of the inflammatory 
site in vivo. In the setting of IBD, it is possible that the inflammatory milieu of the inflamed gut alters 
Treg functional properties, rendering them non-suppressive or even pathogenic [156]. Support for this 
hypothesis comes from the observation that, in the intestinal mucosa of IBD patients, the expression 
of the IL1β and IL6 genes is higher compared to that of control subjects [136]. These cytokines have 
previously been implicated in the development of Th17 cells [157, 158]. In line with this, the numbers 
of IL17pos cells and IL17 mRNA expression are higher in the lamina propria of IBD patients 
compared to controls [136, 159], suggesting that pro-inflammatory skewing of intestinal Tregs could 
be a pathogenic feature of IBD.  
6. Regulatory T cells in autoimmune liver disease 
There are three liver diseases with recognised autoimmune component to their pathogenesis; primary 
biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH).  
PBC is characterised by progressive destruction of the small intrahepatic bile ducts, leading to 
cholestasis, portal inflammation, fibrosis and potentially cirrhosis and liver failure [160].  
The first indications that Tregs may be defective in PBC originate in the 1980s [161]. More recently, 
studies have shown a reduced frequency of circulating CD4posCD25pos/high [162, 163] or 
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CD4posFOXP3pos [164] cells in PBC patients, although in another study, no numerical CD4posCD25pos 
Treg defect was observed [165].  
Magnetically isolated CD4posCD25pos cells from PBC patients have no notable impairment in 
suppressive function [162, 165]. At variance with CD4posCD25pos, the CD8posCD28neg Treg subset was 
found to be less able to suppress proliferation in PBC compared to health [165]. Studies examining 
the livers of PBC patients have reported increased frequencies of FOXP3pos cells compared to controls 
[163, 166]. Moreover, the frequency of FOXP3pos cells positively correlates with the degree of portal 
inflammation [166]. These observations could be indicative of elevated activation-induced FOXP3 
expression on non-regulatory T cell subsets or of increased migration of Tregs to the site of 
inflammation. Although functional CD4posCD25pos Treg defects in PBC have not been observed in 
vitro, it remains possible that the microenvironment of the inflamed liver renders Tregs unable to 
adequately suppress. In support of this, studies have demonstrated increased IFNγ expression in the 
bile ducts of PBC patients [163]. An imbalance between Treg and Th17 cells has also been reported in 
PBC; in peripheral blood mononuclear cells, the gene expression of IL1β, IL6, IL23, RORγt and 
IL17A were higher in PBC compared to health, whereas TGFβ and FOXP3 gene expression was 
lower in PBC patients compared to HS. Similarly, the serum IL1β, IL6 and IL23 concentrations were 
higher in PBC compared to health [164, 167]. 
PSC is characterised by diffuse inflammation and fibrosis of the intra- and extra-hepatic bile ducts, 
eventually progressing to biliary cirrhosis, portal hypertension and hepatic failure. Sebode et al. 
(2014) have recently reported that circulating CD4posCD25highFOXP3posCD127low cells are reduced in 
frequency in PSC patients, demonstrating that these cells are also less able to suppress proliferation. 
Similarly, a reduced number of intrahepatic CD3posFOXP3pos cells were found in biopsies taken at 
diagnosis from PSC patients compared to patients with PBC [168].  In line with this, a number of 
studies, focusing on Tregs in AIH, have included a subset of patients with the autoimmune 
hepatitis/sclerosing cholangitis overlap syndrome, autoimmune sclerosing cholangitis. These studies 
have reported decreased circulating Treg frequencies and impaired suppressive function [57, 169, 
170]. On the other hand, Oo et al. (2010) examined explanted livers from patients with autoimmune or 
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chronic inflammatory liver diseases, some of whom had PSC, and reported a higher frequency of 
liver-infiltrating CD4posCD25posFOXP3posCD127neg Tregs relative to HS. Moreover, isolated 
CD4posCD25pos Tregs from these patients were able to suppress proliferation in vitro [171]. 
In contrast to the two cholestatic autoimmune liver diseases, PBC and PSC, the targets of the 
autoimmune attack in AIH are the hepatocytes themselves. Associated with AIH are a histological 
picture of interface hepatitis, a biochemical pattern characterised by elevated aspartate 
aminotransferase levels, and positivity for circulating autoantibodies. 
The first studies describing ‘suppressor cell’ defects in AIH were performed in the 1970s and 80s 
[172-174].  Since then, lower circulating frequencies of CD4posCD25pos [170, 175] or CD4posCD25high 
[57, 176] Tregs have been reported in AIH patients compared to health, and this defect is associated 
with lower FOXP3 expression [169, 176]. Moreover, during immunosuppressive therapy, the 
circulating Treg frequency has been shown to increase, though not reaching levels seen in health [170, 
176]. In one study, however, the circulating frequency of CD4posCD25highCD127neg FOXP3pos cells 
was equal in AIH patients and healthy subjects, and the frequency of this population was higher in 
patients with active disease compared to those in remission [177]. This discrepancy is likely to be due 
to differences in technical and methodological approaches [178, 179].  
In co-culture with CD4posCD25neg cells, magnetically isolated CD4posCD25pos Tregs from AIH patients 
were less able to generate an anti-inflammatory cytokine milieu rich in TGFβ, suggesting that Tregs 
from AIH patients are ineffective promoters of linked-suppression [169]. Magnetically isolated 
CD4posCD25pos Tregs from AIH patients have been shown to be impaired in their ability to suppress 
the proliferation of CD8pos [175] and of CD4posCD25neg [57, 169, 176, 180] cell populations compared 
to health. CD4posCD25pos Tregs from AIH patients are also ineffective suppressors of IFNγ production 
by CD8 T cells [175]. Additionally, Tregs from AIH patients, but not HS, enhance the activation of 
pro-inflammatory monocytes, by elevating the level of spontaneous migration and by increasing the 
production of TNFα and the expression of TLR4 [181]. Magnetically isolated 
CD4posCD25posCD127neg Tregs from AIH patients were also less able to suppress proliferation than 
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from HS [57], although this defect was not observed in FACS isolated CD4posCD25highCD127neg cells 
[177]. The discrepant results reported in AIH are likely to derive from differences in methodology, 
patient demography, disease activity and type of treatment [182, 183]. 
Tregs from AIH patients have also been shown to express lower levels of Galectin-9, and this defect 
is mirrored by reduced expression of the Galectin-9 ligand, TIM-3, by CD4posCD25neg cells, 
suggesting that AIH may also be associated with effector cell resistance to Treg control [57]. 
We have recently observed that AIH is associated with lower frequencies of CD39pos Tregs. In this 
condition, Tregs fail to adequately hydrolyse pro-inflammatory nucleotides and to suppress the 
production of IL17 by effector CD4 T cells. CD39pos Tregs from AIH patients were also unstable 
upon pro-inflammatory challenge [184], suggesting that defective immuno-regulation in AIH might 
result not only from reduced Treg number and function but also from increased conversion of Tregs 
into effector cells. 
7. Conclusion 
Treg defects are frequently reported in autoimmune disease. There are, however, often discrepancies 
in the literature, which can be accounted for by the choice of study participants and the techniques 
used to study this challenging population of cells. The search for new markers that could 
unequivocally identify bona fide human Tregs – for the purposes of both phenotypic and functional 
analysis – will greatly facilitate our understanding of the role of Tregs in autoimmune disease. Studies 
suggest that the nature of the Treg impairment differs according to the autoimmune disease under 
investigation. There are reports of numerical and functional Treg impairments, of resistance of 
effector T cells to Treg suppression and of conversion of Tregs to effector cells (Figure 1, B). It is, 
therefore, important to consider numerical, phenotypic and functional defects affecting a range of 
Treg subsets. Moreover, current evidence strongly implies that systemic or regional factors can 
confine Treg impairments to the target organ. Treg studies would, therefore, benefit from more 
thorough investigation of the inflammatory site.  
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